Through a diversified and differentiated business model of marketing, out-licensing with supply agreements and contract manufacturing, Intas has achieved PAN European presence. Intas’ core strategy in Europe has been to leverage its hospital network for own/in the licensed pipeline of injectables and target marketing of oral generics in markets of North/West Europe. The acquisition of Actavis UK and Ireland business in 2016 catapulted Intas amongst the top 3 players in the UK and Ireland Generics market.
In total, Intas has 8,500+ product registrations in the European market and strong product pipeline for day 1 launch of products in the market. Intas is a leader in the oncology market with a supportive product basket for every stage and indication of cancer. The company currently has 35 oncology molecules in the market with 5 more planned over the next 12 months.
Intas’ exceptional European pipeline consists of a complex product portfolio. Over 4000 product launches including exclusive 60 day 1 launches are planned in the next 5 years.
Comments
Post a Comment